Saxagliptin Efficacy and Safety in Patients with Type 2 Diabetes Mellitus Stratified by Cardiovascular Disease History and Cardiovascular Risk Factors: Analysis of 3 Clinical Trials
暂无分享,去创建一个
[1] N. Mikhail. Effects of incretin-based therapy in patients with heart failure and myocardial infarction , 2014, Endocrine.
[2] Deepak L. Bhatt,et al. Abstract 17503: Outcomes of Patients With Type 2 Diabetes and Known Congestive Heart Failure Treated With Saxagliptin: Analyses of the SAVOR-TIMI 53 Study , 2013 .
[3] Craig Wilson,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.
[4] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[5] A. Farmer,et al. All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database , 2013, Diabetes Care.
[6] W. White,et al. Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus , 2013, Diabetes, obesity & metabolism.
[7] R. Frederich,et al. Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease History or Cardiovascular Risk Factors: Results of a Pooled Analysis of Phase 3 Clinical Trials , 2013, Postgraduate medicine.
[8] J. McGill,et al. AACE comprehensive diabetes management algorithm 2013. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[9] H. Woerle,et al. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials , 2013, Cardiovascular Diabetology.
[10] G. Paolisso,et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. , 2013, Atherosclerosis.
[11] P. Hsu,et al. Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes , 2013, Diabetes Care.
[12] S. Inzucchi,et al. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.
[13] M. Monami,et al. Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials , 2013, Diabetes, obesity & metabolism.
[14] A. Scheen,et al. Cardiovascular effects of gliptins , 2013, Nature Reviews Cardiology.
[15] N. Sattar,et al. Revisiting the links between glycaemia, diabetes and cardiovascular disease , 2013, Diabetologia.
[16] V. Basevi. Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.
[17] Robert A Greevy,et al. Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus , 2012, Annals of Internal Medicine.
[18] N. Berglind,et al. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial , 2012, Diabetology & Metabolic Syndrome.
[19] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[20] B. Charbonnel,et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin , 2012, Current medical research and opinion.
[21] M. Netea,et al. Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes , 2011, Diabetes Care.
[22] J. Eriksson,et al. Saxagliptin is non‐inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52‐week randomised controlled trial , 2010, International journal of clinical practice.
[23] Joshua J. Neumiller,et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[24] S. Dejager,et al. Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population , 2010, Diabetes, obesity & metabolism.
[25] K. Mahaffey,et al. A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes , 2010, Postgraduate medicine.
[26] A. Avogaro,et al. The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes , 2010, Diabetes Care.
[27] P. Elliott,et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database , 2009, BMJ : British Medical Journal.
[28] P. Hollander,et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. , 2009, The Journal of clinical endocrinology and metabolism.
[29] C. Aguilar-Salinas,et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes , 2009, Current medical research and opinion.
[30] A. Apanovitch,et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial , 2009, International journal of clinical practice.
[31] E. Allen,et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial , 2009, Diabetes, obesity & metabolism.
[32] R. DeFronzo,et al. The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone , 2009, Diabetes Care.
[33] J. Pou,et al. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study , 2009, Journal of the American Academy of Nurse Practitioners.
[34] D. Drucker,et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.
[35] D. Drucker. The biology of incretin hormones. , 2006, Cell Metabolism.
[36] Mark D. Huffman,et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.
[37] H. Woerle,et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme , 2012, Cardiovascular Diabetology.